News
Public · Published
CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position
CorMedix reported approximately $355 million in unaudited cash and cash equivalents as of September 30, 2026, and reaffirmed its 2026 total revenue guidance of $325 million to $345 million. It also said the CMS-set DefenCath add-on payment for the first quarter of 2027 will be $8.32 per dialysis session.
Published:
Updated:
What happened
CorMedix reported approximately $355 million in unaudited cash and cash equivalents as of September 30, 2026, and reaffirmed its 2026 total revenue guidance of $325 million to $345 million. It also said the CMS-set DefenCath add-on payment for the first quarter of 2027 will be $8.32 per dialysis session.
Confirmed
Global impact / market context
The $8.32 payment per dialysis session is a set add-on to the payment system for dialysis services. It may support revenue from DefenCath, but actual sales depend on how many sessions use the product; the article gives no utilization forecast or complete quarterly results.
Analyst inference
The company says the first-quarter 2027 add-on falls within its previously guided range of three to five times the current $2.37 payment. CMS also introduced a quarterly adjustment process, so later payment levels may change; CorMedix says it has not provided data to estimate them.
Analyst inference
What to watch
- CorMedix’s November 12 conference call is expected to provide its complete quarterly financial performance, adding detail beyond the cash position and annual revenue guidance reported here. Confirmed
- Watch for CMS’s quarterly adjustment process to clarify later 2027 add-on payments; those payment levels could affect revenue earned per DefenCath dialysis session. Analyst inference
- Compare future reported revenue with the reaffirmed $325 million to $345 million 2026 guidance, while checking whether the company gives new information on product use. Analyst inference